Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma episode artwork

EPISODE · Aug 5, 2022 · 59 MIN

Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma

from MIB Agents OsteoBites and osTEAo · host MIB Agents Osteosarcoma

This episode is sponsored by the Osteosarcoma Institute (OSI), a nonprofit organization led by osteosarcoma experts from top U.S. cancer centers who, together, are concentrating on the cure ® for osteosarcoma. The mission of the OSI is to dramatically increase treatment options and survival rates in osteosarcoma patients through identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science. In addition to advancing research, OSI also provides a free resource called OSI Connect for osteosarcoma patients. Our osteosarcoma experts can discuss available treatments, possible side effects, and provide helpful advice for getting the most out of your visits with your treating physician. This resource is available in English and Spanish and aims to help patients and families find answers to their questions. -- John A. Ligon, MD, is an assistant professor in the department of pediatrics at the University of Florida College of Medicine. Dr. Ligon earned his medical degree from the Baylor College of Medicine in Houston. After he completed his residency in pediatrics at the University of Texas Southwestern Medical Center in Dallas, he pursued a fellowship in pediatric hematology and oncology at Johns Hopkins University and the National Cancer Institute in Maryland. In the following years, he completed a senior fellowship in pediatric immunotherapy at the National Cancer Institute and another in pediatric sarcoma at Johns Hopkins University. Dr. Ligon is board-certified in both general pediatrics and pediatric hematology and oncology by the American Board of Pediatrics. In addition to his numerous original research publications and editorial review appointments, he is a member of various professional societies, such as the Children’s Oncology Group and the American Association for Cancer Research. Dr. Ligon has been honored with a variety of awards for his research skills and academic excellence. His research interests include immunotherapy, tumors and bloodstream infections.

Episode metadata supplied by the publisher feed · Published Aug 5, 2022

Embed this episode

NOW PLAYING

Using RNA-Nanoparticle Vaccines to Overcome the Immunosuppressive Tumor Microenvironment of Canine Osteosarcoma

0:00 59:43

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MIB Agents OsteoBites and osTEAo?

This episode is 59 minutes long.

When was this MIB Agents OsteoBites and osTEAo episode published?

This episode was published on August 5, 2022.

Can I download this MIB Agents OsteoBites and osTEAo episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!